Kura Oncology Announces First Patients Dosed in Phase 2 Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Kura Oncology Inc., a clinical-stage biopharmaceutical company dedicated to realizing the promise of precision medicines for cancer treatment, announced today that the first patients in its KOMET-001 Phase II registration-directed trial of ziftomenib, the Company’s novel menin inhibitor, in patients with NPM1-mutant relapsed or refractory acute myeloid leukaemia (AML) have been dosed.

Publish Date: 09-02-2023 Source: Kura Oncology Inc.

Acute myeloid leukemia (AML) is the most common type of adult leukemia, but it has the lowest survival rate of all leukemias. Although rates have improved remarkably in the younger age group, the prognosis in older patients continues to be very poor. Chemotherapeutic agents, such as alkylating agents and topoisomerase II inhibitors, have been reported to increase the incidence of AML. Several other substances have been linked to an increased risk of AML. Chronic exposure to certain chemicals clearly shows an increased risk for the development of AML. Benzene is the best-studied and most widely used potentially a leukemogenic agent.

AML is a malignant disorder of the bone marrow characterized by the clonal expansion and differentiation arrest of myeloid progenitor cells. The age-adjusted incidence of AML is 4.3 per 100,000 annually in the United States (US).
It has been estimated that approximately 22,850 adults will be diagnosed with AML in 2020; it accounts for the highest percentage (62%) of leukemic deaths.

However, the current Acute Myeloid Leukemia (AML) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Uproleselan, Entospletinib, Sapacitabine, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Acute Myeloid Leukemia treatment. The key companies in the advanced development stage are GlycoMimetics Incorporated, Kronos Bio, Cyclacel Pharmaceuticals, Inc., etc.. targeting AML.

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Acute Myeloid Leukemia (AML) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.